CRIZOCENT 250 MG
Presentation Crizocent 250: Each capsule contains Crizotinib INN 250 mg Description Crizotinib is an inhibitor of receptor tyrosine kinases including
CRIZONIX 250 MG
Crizonix Capsule 250 mg Indications Crizotinib is a kinase inhibitor indicated for the treatment of patients with- Metastatic non-small cell lung
ELBONIX 50 MG
COMPOSITION Elbonix 50 tablet : Each film coated tablet contains EltrombopagOlamine INN equivalent to Eltrombopag 50 mg. Therapeutic class: Hematopoietic Agent PHARMACOLOGICAL
ELOPAG 25 MG
Elopag Tablet Eltrombopag Olamine 25 mg Everest Pharmaceuticals Ltd. Indications Eltrombopag Olamine is indicated in Chronic Immune (Idiopathic) Thrombocytopenia, Chronic Hepatitis
HEPANIB 200 MG
Hepanib Tablet Sorafenib Tosylate 200 mg Everest Pharmaceuticals Ltd. Indications Hepatocellular Carcinoma: Sorafenib is indicated for the treatment of patients with
HERNIX 40 MG
Hernix Tablet Neratinib 40 mg Beacon Pharmaceuticals Ltd. Indications Neratinib is a kinase inhibitor indicated for the extended adjuvant treatment of
LAPANIX 250 MG
LAPANIX 250 MG Lapatinib Beacon Pharmaceuticals Ltd. Product Description: Lapatinib, a 4-anilinoquinazoline, is an inhibitor of the intracellular tyrosine kinase
LARONIB 100 MG
DESCRIPTION Laronib Larotrectinib 25 mg & 100 mg COMPOSITION LARONIB 25 capsules: Each capsule contains Larotrectinib Sulfate INN equivalent to
LENVANIX 10 MG
Lenvanix (lenvatinib) 10 Mg Product Description: First new frontline treatment option for HCC approved in Japan Lenvatinib is amultikinase inhibitor
LUCISUN 50
Brand name: LUCISUN 50 Pack: Pack of 28 capsules Key ingredient: Sunitinib Description LUCISUN 50 provides targeted therapy against various cancers.
NEXANIB 200 MG
Nexanib Tablet Sorafenib Tosylate 200 mg Julphar Bangladesh Ltd. Indications Hepatocellular Carcinoma: Sorafenib is indicated for the treatment of patients with